269 related articles for article (PubMed ID: 25690099)
1. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
[TBL] [Abstract][Full Text] [Related]
2. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
[TBL] [Abstract][Full Text] [Related]
3. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
[TBL] [Abstract][Full Text] [Related]
6. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
[TBL] [Abstract][Full Text] [Related]
7. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
9. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
[TBL] [Abstract][Full Text] [Related]
11. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
[TBL] [Abstract][Full Text] [Related]
13. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
[TBL] [Abstract][Full Text] [Related]
14. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
[TBL] [Abstract][Full Text] [Related]
15. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.
Roeffen W; Theisen M; van de Vegte-Bolmer M; van Gemert G; Arens T; Andersen G; Christiansen M; Sevargave L; Singh SK; Kaviraj S; Sauerwein R
Malar J; 2015 Nov; 14():443. PubMed ID: 26552428
[TBL] [Abstract][Full Text] [Related]
16. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
McGuire KA; Miura K; Wiethoff CM; Williamson KC
Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
[TBL] [Abstract][Full Text] [Related]
17. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
Kumar R; Angov E; Kumar N
Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
[TBL] [Abstract][Full Text] [Related]
18. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
